Status:
ENROLLING_BY_INVITATION
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
Lead Sponsor:
Shanghai East Hospital
Conditions:
Diabetes Mellitus, Type 2
Nicotine Dependence, Cigarettes
Eligibility:
MALE
18-75 years
Phase:
NA
Brief Summary
Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, repre...
Detailed Description
Diabetes has become an increasingly severe global health concern. In 2021, an estimated 537 million adults worldwide were living with diabetes, and this number is projected to rise to 783 million by 2...
Eligibility Criteria
Inclusion
- Male patients aged 18-75 years.
- Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria.
- A history of smoking for at least one year.
- Fagerström Test for Nicotine Dependence (FTND) score ≥4.
- Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications.
- Patients who fully understand the study, voluntarily participate, and sign the informed consent form.
Exclusion
- Diagnosis of type 1 diabetes or other specific types of diabetes.
- Presence of diabetic ketoacidosis or severe diabetic complications.
- Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases.
- Presence of severe infections, malignancies, recent surgeries, or major trauma.
- A history of severe recurrent hypoglycemia.
- Severe gastrointestinal disorders, such as gastroparesis.
- Poor adherence or inability to attend scheduled follow-up visits.
- A history of pancreatitis or a high risk of developing pancreatitis.
- Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability.
- Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia.
- \-
Key Trial Info
Start Date :
June 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06924697
Start Date
June 21 2025
End Date
July 1 2026
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai
Shanghai, Shanghai Municipality, China, 200120